| Old Articles: <Older 6641-6650 Newer> |
|---|
 |
HBS Working Knowledge
August 30, 2010
Julia Hanna |
Turning Employees Into Problem Solvers Patient-safety information campaigns can help hospital staff do more than just report problems when they occur. By serving as role models, managers who actively engage in problem solving can lead their frontline workers to create and share solutions.   |
The Motley Fool
August 30, 2010
Seth Jayson |
Is Affymetrix Growing or Slowing? Is Affymetrix sending any warning signs? Take a look at its accounts receivable and days sales outstanding to find out. |
The Motley Fool
August 30, 2010
Brian Orelli |
It's a Blockbuster ... Maybe On the surface, sanofi-aventis' oral multiple sclerosis drug teriflunomide looks like a hit. But below the surface? |
The Motley Fool
August 30, 2010
Brian Orelli |
Maybe Not a Blockbuster, But We'll Take It Novartis' newest addition, blood pressure medication Tekamlo, isn't going to rocket to the top of the 2020 best seller list, but it's still a nice addition nonetheless. |
The Motley Fool
August 30, 2010
Ilan Moscovitz |
Pfizer: Dividend Dynamo or Disaster? The stability and growth of Pfizer's dividend will depend on its ability to continue to develop and grow its pipeline of drugs and successfully integrate Wyeth. |
The Motley Fool
August 30, 2010
Ryan McBride |
Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams. |
The Motley Fool
August 29, 2010
Jeremy Phillips |
Is Trouble Ahead for Intuitive Surgical? Does this highly-shorted stock deserve it? |
The Motley Fool
August 29, 2010
Jeremy Phillips |
Time to Short Orthovita? With a PEG ratio greater than 1.5, short interest is likely targeting Orthovita on account of its significant P/E premium relative to its growth potential. |
The Motley Fool
August 28, 2010
Todd Wenning |
Dividend Report Card: Johnson & Johnson Does this health-care titan's dividend pass the test? |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much. |
| <Older 6641-6650 Newer> Return to current articles. |
